That means its approval status, access routes, labeling, and routine clinical use may differ from medicines that already have formal regulatory approval
Obesity leads to chronic inflammation, he said, and that inflammation has very clear effects on your arteries and your cardiovascular system. Reducing that inflammation with GLP-1s, it turns out, reduces cardiovascular risk
After matching, the analysis included 546 GLP-1 receptor agonist users and 546 non-users with similar baseline characteristics
When they become too short, the cell can no longer replicate and becomes senescent (biologically aged) or dies
Clinical trials have shown that patients receiving both medications experience greater reductions in body weight and HbA1c levels compared to those on tirzepatide alone
Book your consultation at Nusbaum Medical Centers today